TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces the results of a market research study conducted with ear, nose, and throat specialists (ENTs or otolaryngologists), concerning their attitudes about the causation of Chronic Sinusitis (CS), the diagnosis, and the management of the disease. Beechwood Associates, Inc., designed the survey, collected data, and performed the analysis. Accentia Pharmaceuticals’ sales representatives called on 950 specialists to ask them to complete the survey and 750, or 78% of those specialists, elected to participate. There are an estimated ten thousand ENT specialists in the U.S., so the sample size represents about 7% of all ENT specialists.
